Tempus AI, Inc. (TEM)
NEUTRALFundamental
41
Kurs
$68.59
Marktkapitalisierung
$13.12B
Teil 1 · Was das Unternehmen wert ist
Übersicht
Tempus sells AI-driven diagnostic tests and the data platform built on top of them. Doctors, mostly oncologists, order its genomic sequencing tests to decide which cancer drugs are likely to work for a specific patient, and the results also add to a growing library of clinical and molecular data. That data library is then licensed to pharmaceutical companies, who use it to find drug targets and design clinical trials faster than they could with their own data alone.
Wie das Geld verdient wird
Diagnostics revenue is billed per test, largely through insurance reimbursement, so it depends on how many tests get ordered and what payers agree to pay for each one. Data and Applications revenue comes from multi-year licensing agreements with pharmaceutical companies and from Insights, a subscription-like product giving structured access to Tempus's data library. The Diagnostics business drives most of the volume and losses today, while Data and Applications carries higher margins and is growing faster.
Umsatz nach Segment
Genomic and molecular sequencing tests ordered by physicians, mainly oncologists, to guide treatment decisions for individual cancer patients.
Licensing of Tempus's clinical and molecular data library to pharmaceutical companies, plus Insights, a subscription product for structured data access.
Wettbewerbsvorteil
Patente und Lizenzen · SchmalTempus's advantage rests on a data library that grows with every test it runs, linking genomic results to real clinical outcomes in a way a newcomer cannot replicate quickly. But established diagnostics competitors have their own large data sets and physician relationships, and nothing stops a hospital system from sending samples to more than one lab.
Was die Nachfrage antreibt
Mäßig zyklischTest volume follows how many patients get diagnosed with cancer and how willing physicians and insurers are to order and pay for genomic profiling, a trend that has grown steadily rather than swung with the economy. Data licensing demand instead tracks pharmaceutical research budgets, which can be cut in a downturn even as clinical demand for testing keeps rising.
Wichtigste Risiken
- Ongoing net losses and cash burn — Tempus has never been profitable and continues to report significant net losses and negative operating cash flow, making it dependent on external financing or faster margin improvement to keep funding growth.
- Reimbursement risk on Diagnostics tests — Insurers can decline to cover a test, pay less than the cost of running it, or change coverage policy, and Diagnostics revenue depends heavily on what payers ultimately reimburse.
- A data-driven model that rivals could replicate — The value of Tempus's data library depends on continuing to add tests and partners at scale; larger, better-capitalized competitors in genomic testing could build comparable data assets over time.
- Regulatory oversight of laboratory-developed tests — Tempus's tests operate as laboratory-developed tests under evolving regulatory frameworks; a shift toward stricter FDA oversight could raise costs or slow the launch of new tests.
Kundenkonzentration
Tempus signed data-licensing agreements with more than 70 pharmaceutical partners in 2025, including large companies such as AstraZeneca and Merck; the company does not disclose what share of revenue its largest partner represents.
Die Argumente dafür
Buyers argue that Tempus is building a data asset pharmaceutical companies cannot easily replicate, that landing repeat, expanding agreements with companies like AstraZeneca and Merck shows the model works commercially, and that Diagnostics volume growth of over 100% signals a business approaching the scale needed to turn a profit.
Die Argumente dagegen
Sellers fear that a company still losing money at this scale depends on continued access to capital markets, that reimbursement for genomic tests can be cut by insurers at any time, and that today's data advantage narrows as competitors with equally large patient populations build their own libraries.
Written by the editors, published on 18. August 2026
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilanz & Liquidität
Umsatz
$1.43B
Letzte 12 Monate (bis 30.6.2026)
Nettogewinn
$-254M
Letzte 12 Monate (bis 30.6.2026)
Freier Cashflow
$-239M
Gesamtes Eigenkapital
$491M
Gesamtverbindlichkeiten
$1.78B
Current Ratio
3.30
Zinsdeckungsgrad
5.12
Schulden/EBITDA
-
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$63.36
Aktueller Kurs
$68.59
Sicherheitsmarge
-8.3%
Innerer-Wert-Spanne
$60.19 - $66.52
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
-
ROE
-49.9%
P/B-Verhältnis
26.08
P/FCF
-
Bruttomarge
-
ROIC
-11.3%
Rentabilitäts-Radar
Value Creation (Economic Moat)
ROIC
-11.3%
WACC
15.7%
ROIC − WACC
-27.1 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamentalanalyse-Kriterien
Bestanden (9)
- EPS shows upward trend
- Price CAGR 46.77%
- Debt/Equity ratio
- Current Ratio
- Interest Coverage
- Revenue Growth 5Y 46.6%
- Analyst Consensus 57% Buy
- Earnings Surprise avg 36.2%
- Net Margin Trend -17.8% vs -21.0%
Nicht bestanden (10)
- ROIC -11.3%
- P/B Ratio 26.08
- Operating Margin -19.8%
- Positive Free Cash Flow
- Return on Tangible Assets
- Low reliance on intangibles
- DCF valuation (Unknown)
- ROE -54.7%
- Share Dilution 53.4%
- Piotroski F-Score 4/9
Nicht verfügbar (8)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Gemischte Signale: Einige Bereiche bedürfen Aufmerksamkeit
Gewinnqualität
Niedrige Qualität: Rechnungslegung prüfen
Aktienverwässerung
Neue Aktien werden ausgegeben, Eigentum wird verwässert
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Mr. Eric P. Lefkofsky J.D. | Co-Founder, CEO, President & Chairman | 55 |
| Mr. James Rogers | Chief Financial Officer | 38 |
| Mr. Erik Phelps | Executive VP and Chief Administrative & Legal Officer | 54 |
| Mr. Andrew Polovin | Chief Legal Officer | 51 |
| Mr. Ryan Fukushima | Chief Executive Officer of Data & Apps | 39 |
| Mr. Ryan M. Bartolucci CPA | Chief Accounting Officer | 43 |
| Mr. Shane Colley | Chief Technology Officer | - |
| Dr. Kate A. Sasser Ph.D. | Chief Scientific Officer | 47 |
| Ms. Elizabeth Krutoholow | Vice President of Investor Relations & Competitive Intelligence | - |
| Ms. Christina Antoniou | Senior VP & Head of Corporate Development | - |
Prüfungsrisiko
1
Vorstandsrisiko
9
Vergütungsrisiko
10
Aktionärsrechterisiko
10
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Latest News
Recent headlines for TEM, sourced from Markets Gazette.
- 6d agoPOSITIVELe azioni Tempus AI volano grazie a Moderna
Tempus AI (TEM) shares surged on August 19th, fueled by a technical short squeeze triggered by positive third-party clinical trial progress. The stock decisively broke above key moving averages, signaling a bullish trend reversal across multiple timeframes. Following this rally, Tempus AI shares are trading nearly 50% above their July lows. The primary catalyst for TEM's explosive move originated not from Tempus AI itself, but from Phase 3 benchmark results released by Merck and Moderna Inc., which indirectly boosted investor sentiment towards health-tech companies like Tempus AI.
- 5/6/2026POSITIVETempus AI's Big Pharma AI Partnerships Are Getting Bigger And Stickier
Tempus AI reported Q1 revenue of $348.1 million, a substantial 36.1% increase year-over-year, surpassing analyst expectations. The company also raised its 2026 financial outlook, citing robust demand for its artificial intelligence solutions and diagnostic services, particularly within the pharmaceutical sector. These strong results and an optimistic forward-looking statement suggest continued growth and market penetration, which is a positive indicator for investors.
- 3/26/2026POSITIVECathie Wood Chooses Medical AI Over Mark Zuckerberg: Ark Loads Up On TEM Stock, Dumps Meta Shares
Cathie Wood's Ark Invest has significantly increased its exposure to the healthcare technology sector by acquiring shares of Tempus AI (TEM). This strategic move contrasts with a simultaneous reduction in Meta Platforms (META) holdings, indicating a pronounced shift in Ark's investment focus. The decision to favor medical AI specialists like Tempus AI over established big tech giants suggests a strong conviction in the growth potential and disruptive capabilities of AI applications within the healthcare industry. Investors may view this as a signal of strong future performance for companies at the intersection of AI and medicine.
- 2/26/2026POSITIVECathie Wood Is Buying The Tempus AI Dip, Ark Snaps Up Stock Worth $11 Million
Cathie Wood's Ark Invest made a notable move on Wednesday, February 25, 2026, by acquiring $11 million worth of Tempus AI stock. This significant purchase followed a 7% dip in the company's share price. Ark Invest's decision to 'buy the dip' signals strong conviction in Tempus AI's long-term prospects and underlying value, particularly in the wake of a market correction. Investors often view such actions by prominent funds like Ark as a bullish indicator, suggesting that the recent downturn presents an an attractive entry point and reinforcing the potential for future growth in the artificial intelligence sector.
- 2/24/2026NEGATIVETempus AI Stock Drops Despite Q4 Earnings Beat: Details
Tempus AI's stock, TEM, experienced a notable decline despite the company reporting stronger-than-expected Q4 earnings. The healthcare AI firm announced robust financial results, yet investor reaction was unexpectedly negative, leading to a drop in share value. This scenario suggests that the market might have already priced in the positive news, or that there are underlying concerns not immediately apparent in the earnings report, such as cautious future outlooks or a perceived overvaluation. Investors should closely monitor upcoming communications to understand the reasons behind this discrepancy.
via Markets Gazette